Published in Mov Disord on April 30, 2008
Cognitive Training in Parkinson Study (cogtips) | NCT02920632
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology (2014) 2.10
Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol (2014) 2.00
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain (2014) 1.70
Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology (2011) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Longitudinal study of normal cognition in Parkinson disease. Neurology (2015) 1.59
Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology (2014) 1.59
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology (2010) 1.58
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol (2010) 1.57
A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One (2013) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology (2010) 1.53
Non-motor features of Parkinson disease. Nat Rev Neurosci (2017) 1.42
Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med (2012) 1.41
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol (2010) 1.41
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet (2014) 1.40
Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology (2013) 1.40
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
Formation and development of Lewy pathology: a critical update. J Neurol (2009) 1.37
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology (2009) 1.37
A review of dual-task walking deficits in people with Parkinson's disease: motor and cognitive contributions, mechanisms, and clinical implications. Parkinsons Dis (2011) 1.31
Amyloid imaging of Lewy body-associated disorders. Mov Disord (2010) 1.27
Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol (2012) 1.26
Effects of deep brain stimulation of the subthalamic nucleus on inhibitory and executive control over prepotent responses in Parkinson's disease. Front Syst Neurosci (2013) 1.22
Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain (2011) 1.22
Mild cognitive impairment in Parkinson's disease. Minerva Med (2011) 1.19
The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord (2014) 1.17
Recurrent falls in Parkinson's disease: a systematic review. Parkinsons Dis (2013) 1.17
Evaluation of novel stimulus waveforms for deep brain stimulation. J Neural Eng (2010) 1.16
Functional brain networks and abnormal connectivity in the movement disorders. Neuroimage (2011) 1.15
Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord (2012) 1.15
The relationship between quality of life and swallowing in Parkinson's disease. Mov Disord (2009) 1.15
Parkinsonian single fallers versus recurrent fallers: different fall characteristics and clinical features. J Neurol (2010) 1.14
Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci (2011) 1.13
Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13
A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord (2010) 1.13
Genetic influences on cognitive decline in Parkinson's disease. Mov Disord (2012) 1.10
Parkinson's disease dementia: a neural networks perspective. Brain (2015) 1.10
Charting the progression of disability in Parkinson disease: study protocol for a prospective longitudinal cohort study. BMC Neurol (2010) 1.08
Capturing ambulatory activity decline in Parkinson's disease. J Neurol Phys Ther (2012) 1.08
Cortical thinning is associated with disease stages and dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry (2013) 1.07
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol (2014) 1.07
What can biomarkers tell us about cognition in Parkinson's disease? Mov Disord (2014) 1.03
Visual spatial cognition in neurodegenerative disease. Neurocase (2010) 1.03
Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol (2014) 1.00
Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One (2013) 1.00
Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol (2012) 0.98
Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants. Neurol Genet (2016) 0.98
Late-stage Parkinson disease. Nat Rev Neurol (2012) 0.97
Detection of freezing of gait in Parkinson disease: preliminary results. Sensors (Basel) (2014) 0.97
The effect of Tai Chi exercise on gait initiation and gait performance in persons with Parkinson's disease. Parkinsonism Relat Disord (2013) 0.96
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Adult neurogenesis in neurodegenerative diseases. Cold Spring Harb Perspect Biol (2015) 0.96
The spectrum of cognitive impairment in Lewy body diseases. Mov Disord (2014) 0.96
Freezing of gait is associated with a mismatch between motor imagery and motor execution in narrow doorways, not with failure to judge doorway passability. Neuropsychologia (2011) 0.96
Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch Neurol (2010) 0.95
The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease. Parkinsonism Relat Disord (2013) 0.95
Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. Eur Arch Psychiatry Clin Neurosci (2014) 0.95
Profile of cognitive impairment in Parkinson's disease. Brain Pathol (2010) 0.95
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord (2015) 0.94
Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging (2012) 0.94
The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. Parkinsons Dis (2012) 0.94
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Eye movements in patients with neurodegenerative disorders. Nat Rev Neurol (2013) 0.91
Identification of the contribution of the ankle and hip joints to multi-segmental balance control. J Neuroeng Rehabil (2013) 0.90
Dopaminergic medication does not improve stepping responses following backward and forward balance perturbations in patients with Parkinson's disease. J Neurol (2014) 0.90
Transcranial magnetic stimulation and transcranial direct current stimulation: treatments for cognitive and neuropsychiatric symptoms in the neurodegenerative dementias? Alzheimers Res Ther (2014) 0.89
Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol (2014) 0.89
Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord (2014) 0.89
Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis (2014) 0.89
Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging (2014) 0.88
Differential effects of duration and age on the consequences of neuroinflammation in the hippocampus. Neurobiol Aging (2013) 0.88
Risk of falls in Parkinson's disease: a cross-sectional study of 160 patients. Parkinsons Dis (2012) 0.88
The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener Dis (2013) 0.88
Genomic determinants of motor and cognitive outcomes in Parkinson's disease. Parkinsonism Relat Disord (2012) 0.87
FDG PET in the Evaluation of Parkinson's Disease. PET Clin (2010) 0.87
The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. J Neurol (2011) 0.87
Neuroimaging of Parkinson's disease: Expanding views. Neurosci Biobehav Rev (2015) 0.87
Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord (2015) 0.87
Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism Relat Disord (2014) 0.86
Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? J Comp Neurol (2014) 0.86
Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord (2012) 0.86
Exercise and motor training in people with Parkinson's disease: a systematic review of participant characteristics, intervention delivery, retention rates, adherence, and adverse events in clinical trials. Parkinsons Dis (2011) 0.86
Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord (2014) 0.85
Impairments of speech fluency in Lewy body spectrum disorder. Brain Lang (2011) 0.85
Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. Sci Rep (2016) 0.85
Parkinson's disease: oxidative stress and therapeutic approaches. Neurol Sci (2010) 0.85
Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) (2015) 0.85
Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun (2015) 0.84
The Vulnerable Ventral Tegmental Area in Parkinson's Disease. Basal Ganglia (2015) 0.84
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Clinicopathological correlates in frontotemporal dementia. Ann Neurol (2004) 4.38
The pathological basis of semantic dementia. Brain (2005) 2.96
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord (2005) 2.68
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol (2008) 2.34
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Neuropathologic correlates of white matter hyperintensities. Neurology (2008) 2.29
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol (2005) 2.14
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Movement disorder emergencies. Mov Disord (2005) 2.09
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Cognitive, extrapyramidal, and magnetic resonance imaging predictors of functional impairment in nondemented older community dwellers: the Sydney Older Person Study. J Am Geriatr Soc (2006) 1.63
Clinical and physiological assessments for elucidating falls risk in Parkinson's disease. Mov Disord (2009) 1.61
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 1.57
Small-vessel disease in patients with Parkinson's disease: a clinicopathological study. Mov Disord (2012) 1.56
Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol (2006) 1.47
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord (2013) 1.44
C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology (2012) 1.44
P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol (2006) 1.43
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. Clin Experiment Ophthalmol (2007) 1.41
Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Mov Disord (2013) 1.39
Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord (2007) 1.39
Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain (2002) 1.27
Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol (2008) 1.26
Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol (2010) 1.24
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol (2010) 1.21
Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J Biol Chem (2002) 1.19
Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol (2004) 1.19
α-Synucleinopathy phenotypes. Parkinsonism Relat Disord (2014) 1.16
Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (2001) 1.12
Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol (2003) 1.10
Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov Disord (2002) 1.10
Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Mov Disord (2002) 1.09
p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol (2007) 1.08
Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain (2003) 1.06
Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord (2011) 1.05
Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol (2012) 1.03
Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol (2011) 1.03
Distribution of brain atrophy in behavioral variant frontotemporal dementia. J Neurol Sci (2005) 1.02
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol (2011) 1.01
Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? Mov Disord (2009) 0.97
The influence of geographical location on the complexity of rural general practice activities. Med J Aust (2003) 0.97
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain (2003) 0.95
Clinicopathological staging of frontotemporal dementia severity: correlation with regional atrophy. Dement Geriatr Cogn Disord (2004) 0.95
Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord (2007) 0.95
Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol (2009) 0.95
Variable phenotype of Alzheimer's disease with spastic paraparesis. J Neurochem (2007) 0.94
GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J Comp Neurol (2012) 0.94
Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol Aging (2006) 0.94
Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol (2010) 0.93
The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Hum Brain Mapp (2013) 0.93
A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord (2004) 0.93
Dolichol is the major lipid component of human substantia nigra neuromelanin. J Neurochem (2005) 0.93
An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids (2013) 0.92
Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging (2009) 0.92
What is the dominant Abeta species in human brain tissue? A review. Neurotox Res (2005) 0.91
Unique transcriptome patterns of the white and grey matter corroborate structural and functional heterogeneity in the human frontal lobe. PLoS One (2013) 0.91
Low serum progranulin predicts the presence of mutations: a prospective study. J Alzheimers Dis (2010) 0.90
Dopa-responsive parkinsonism secondary to right temporal lobe haemorrahage. Mov Disord (2002) 0.90
Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Mov Disord (2010) 0.89
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain (2004) 0.89
Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm (Vienna) (2009) 0.89
Neurofilament-immunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiol Dis (2002) 0.88
Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol (2002) 0.87
Visual hallucinations in Parkinson's disease: theoretical models. Mov Disord (2014) 0.87
Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiol Dis (2004) 0.87
Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutation. Transl Neurodegener (2012) 0.87
DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov Disord (2013) 0.86
Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. J Parkinsons Dis (2013) 0.86
The neural basis of semantic memory: evidence from semantic dementia. Neurobiol Aging (2008) 0.86
Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. Biochemistry (2005) 0.86
Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. J Neurol (2004) 0.86
Aspects of innate immunity and Parkinson's disease. Front Pharmacol (2012) 0.85
FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS One (2013) 0.84
Pathological staging of frontotemporal lobar degeneration. J Mol Neurosci (2011) 0.84
Increased expression of ABCA8 in multiple system atrophy brain is associated with changes in pathogenic proteins. J Parkinsons Dis (2013) 0.83
ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun (2013) 0.83
Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease. Acta Neuropathol (2008) 0.83
Effect of age on proliferation-regulating factors in human adult neurogenic regions. J Neurochem (2010) 0.83
Longitudinal white matter changes in frontotemporal dementia subtypes. Hum Brain Mapp (2013) 0.82
Utility and limitations of Addenbrooke's Cognitive Examination-Revised for detecting mild cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord (2011) 0.82
Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Res Bull (2008) 0.82
Dysexecutive behaviour following deep brain lesions--a different type of disconnection syndrome? Cortex (2011) 0.82
An emerging role for LRRK2 in the immune system. Biochem Soc Trans (2012) 0.82
Is seladin-1 really a selective Alzheimer's disease indicator? J Alzheimers Dis (2012) 0.82
Increased ATP-binding cassette transporter A1 expression in Alzheimer's disease hippocampal neurons. J Alzheimers Dis (2010) 0.81
The relationship between clinical and pathological variables in Richardson's syndrome. J Neurol (2011) 0.81
Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. Mov Disord (2009) 0.81
Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation. Neurotox Res (2005) 0.81
Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. Neuroreport (2002) 0.81
Srp20 regulates TrkB pre-mRNA splicing to generate TrkB-Shc transcripts with implications for Alzheimer's disease. J Neurochem (2012) 0.81
Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neurosci (2010) 0.81
Staging disease severity in movement disorder tauopathies: brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. Mov Disord (2005) 0.80
Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology. Brain (2010) 0.80